Can we improve on ibrutinib in mantle cell lymphoma?
Mené sur 50 patients atteints d'un lymphome à cellules du manteau réfractaire ou récidivant, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité d'un traitement combinant ibrutinib, lénalidomide et rituximab, après l'échec d'une ou de plusieurs lignes thérapeutiques à base de rituximab
Mantle cell lymphoma is a challenging disease to treat. Although front-line therapy is reasonably well established in this disease, relapse remains inevitable. In this setting, the standard of care for most patients has been to switch to an alternative immunochemotherapeutic option. However, responses are often incomplete, short lived, and accompanied by the usual chemotherapy-associated toxicity. It is in this setting that Bruton's tyrosine kinase (BTK) inhibitors offer a significant advantage.